<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CAFERGOT- ergotamine tartrate and caffeine tablet </strong><br>KAISER FOUNDATION HOSPITALS<br></p></div>
<h1>CAFERGOT<span class="Sup">®</span> (Ergotamine Tartrate and Caffeine) Tablets, USP<br>1 mg/ 100 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1><span class="Bold">Rx only</span></h1>
<div class="Warning">
<a name="section-1.1"></a><p></p>
<h2>WARNING</h2>
<p class="First"><span class="Bold">Serious and/or life-threatening <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span> has been associated with the coadministration of CAFERGOT<span class="Sup">®</span> with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics.  Because CYP 3A4 inhibition elevates the serum levels of CAFERGOT<span class="Sup">®</span>, the risk for <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> leading to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities is increased.  Hence, concomitant use of these medications is contraindicated.</span>(<span class="Bold Italics">See also </span><span class="Bold">CONTRAINDICATIONS</span><span class="Bold Italics"> and </span><span class="Bold">WARNINGS</span><span class="Bold Italics"> section</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each tablet for oral administration contains 1 mg ergotamine tartrate, USP, and 100 mg caffeine, USP.</p>
<p>ERGOTAMINE TARTRATE:</p>
<div class="Figure"><img alt="Ergotamine Tartrate Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1c066197-dea6-4705-9b4a-8703dd564a2a&amp;name=Cafergot-01.jpg"></div>
<p>(C<span class="Sub">33</span>H<span class="Sub">35</span>N<span class="Sub">5</span>O<span class="Sub">5</span>)<span class="Sub">2</span>• C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">6</span>                                                                                  M.W. 1313.41</p>
<p>Ergotaman-3’, 6’, 18-trione, 12’-hydroxy-2’-methyl-5’-(phenyl-methyl)-, (5’α), [R-(R*, R*)]-2,3-dihydroxy-butanedioate (2:1) (salt)</p>
<p>CAFFEINE:</p>
<div class="Figure"><img alt="Caffeine Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1c066197-dea6-4705-9b4a-8703dd564a2a&amp;name=Cafergot-02.jpg"></div>
<p>C<span class="Sub">8</span>H<span class="Sub">10</span>N<span class="Sub">4</span>O<span class="Sub">2</span>  (anhydrous)                                                                                 M.W. 194.19</p>
<p>1<span class="Italics">H</span>-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-</p>
<p>Inactive ingredients include black iron oxide, compressible sugar, iron oxide red, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, sodium starch glycolate, talc, titanium dioxide and yellow iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of central vasomotor centers.  The compound also has the properties of serotonin antagonism.  In comparison to hydrogenated ergotamine, the adrenergic blocking actions are less pronounced and vasoconstrictive actions are greater.  </p>
<p>Caffeine, also a cranial vasoconstrictor, is added to further enhance the vasoconstrictive effect without the necessity of increasing ergotamine dosage.</p>
<p>Many <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> patients experience excessive <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> during attacks, making it impossible for them to retain any oral medication.  In such cases, therefore, the only practical means of medication is through the rectal route where medication may reach the cranial vessels directly, evading the splanchnic vasculature and the liver.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics:</h2>
<p class="First"><span class="Bold">Interactions: </span>  <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic interactions</span> (increased blood levels of ergotamine) have been reported in patients treated orally with ergotamine and macrolide antibiotics (e.g., troleandomycin, clarithromycin, erythromycin), and in patients treated orally with ergotamine and protease inhibitors (e.g. ritonavir) presumably due to inhibition of cytochrome P450 3A metabolism of ergotamine (See <span class="Bold">CONTRAINDICATIONS</span>).  Ergotamine has also been shown to be an inhibitor of cytochrome P450 3A catalyzed reactions.  No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> involving other cytochrome P450 isoenzymes are known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) are indicated as therapy to abort or prevent <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headache</span>; e.g., <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> variants or so-called "histaminic cephalalgia".</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Coadministration of ergotamine with potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (<span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span>) characterized by <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities (see <span class="Bold">PRECAUTIONS: Drug Interactions</span>), with some cases resulting in amputation.  There have been rare reports of <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> in patients on protease inhibitor therapy when CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) was coadministered, at least one resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Because of the increased risk of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of CYP 3A4 (e.g., ketoconazole, itraconazole) (see <span class="Bold">WARNINGS: CYP 3A4 Inhibitors</span>). </p>
<p>CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) may cause fetal harm when administered to pregnant women. CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this product, the patient should be apprised of the potential hazard to the fetus.</p>
<p><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, impaired hepatic or renal function and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any of the components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors):</span>  Coadministration of ergotamine with potent CYP 3A4 inhibitors such as protease inhibitors or macrolide antibiotics has been associated with serious adverse events; for this reason, these drugs should not be given concomitantly with ergotamine <span class="Italics">(See </span><span class="Bold">CONTRAINDICATIONS</span><span class="Italics">)</span>.  While these reactions have not been reported with less potent CYP 3A4 inhibitors, there is a potential risk for serious toxicity including <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> when these drugs are used with ergotamine.  Examples of less potent CYP 3A4 inhibitors include:  saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton,  metronidazole, and clotrimazole.  These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with ergotamine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7"></a><p></p>
<h1>Fibrotic Complications:</h1>
<p class="First">There have been a few reports of patients on ergotamine and caffeine therapy developing retroperitoneal and/or pleuropulmonary <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>.  There have also been rare reports of fibrotic thickening of the aortic, mitral, tricuspid, and/or pulmonary valves with long-term continuous use of ergotamine and caffeine.  Ergotamine tartrate should not be used for chronic daily administration (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">General:</p>
<p>Although signs and symptoms of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> rarely develop even after long term intermittent use, care should be exercised to remain within the limits of recommended dosage.</p>
<p><span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">Ergotism</span> is manifested by intense arterial <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, producing signs and symptoms of peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>. Ergotamine induces <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> by a direct action on vascular smooth muscle. In chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with ergot derivatives, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span>, and <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> of the digits may occur. If the condition is allowed to progress untreated, <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> can result.</p>
<p>While most cases of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> associated with ergotamine treatment result from frank overdosage, some cases have involved apparent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. There are few reports of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> among patients taking doses within the recommended limits or for brief periods of time. In rare instances, patients, particularly those who have used the medication indiscriminately over long periods of time, may display withdrawal symptoms consisting of rebound <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> upon discontinuation of the drug.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-9"></a><p></p>
<h1>Information for Patients:</h1>
<p class="First">Patients should be advised that two tablets of CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) should be taken at the first sign of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>.  No more than 6 tablets should be taken for any single <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack.  No more than 10 tablets should be taken during any 7-day period.  Administration of ergotamine and caffeine tablets should not exceed the dosing guidelines and should not be used for chronic daily administration (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>).  CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) should be used only for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>.  It is not effective for other types of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and it lacks analgesic properties.  Patients should be advised to report to the physician immediately any of the following:  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the fingers and toes, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> in the arms and legs, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in the legs, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest or temporary speeding or slowing of the heart rate, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-10"></a><p></p>
<h1>Drug Interactions:</h1>
<p class="First"><span class="Bold">CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors):</span>
  See CONTRAINDICATIONS and WARNINGS</p>
<p>CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) should not be administered with other vasoconstrictors.  Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure.  The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) by blocking the vasodilating property of epinephrine.  Nicotine may provoke <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> in some patients, predisposing to a greater ischemic response to ergot therapy.</p>
<p>The blood levels of ergotamine-containing drugs are reported to be elevated by the concomitant administration of macrolide antibiotics and vasospastic reactions have been reported with therapeutic doses of the ergotamine-containing drugs when coadministered with these antibiotics.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-11"></a><p></p>
<h1>Pregnancy:</h1>
<p class="First"><span class="Bold">Teratogenic Effects:</span></p>
<p>Pregnancy Category X:  There are no studies on the placental transfer or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> of the combined products of CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP). Caffeine is known to cross the placenta and has been shown to be teratogenic in animals. Ergotamine crosses the placenta in small amounts, although it does not appear to be embryotoxic in this quantity. However, prolonged <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> of the uterine vessels and/or increased myometrial tone leading to reduced myometrial and placental blood flow may have contributed to <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span> observed in animals.  <span class="Italics">(See </span><span class="Bold">CONTRAINDICATIONS</span><span class="Italics">)</span></p>
<p>Nonteratogenic Effects: CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) is contraindicated in pregnancy due to the oxytocic effects of ergotamine.  <span class="Italics">(See </span><span class="Bold">CONTRAINDICATIONS</span><span class="Italics">)</span></p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-12"></a><p></p>
<h1>Labor and Delivery:</h1>
<p class="First">CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) is contraindicated in labor and delivery due to its oxytocic effect which is maximal in the third trimester.  <span class="Italics">(See </span><span class="Bold">CONTRAINDICATIONS</span><span class="Italics">)</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-13"></a><p></p>
<h1>Nursing Mothers:</h1>
<p class="First">Ergot drugs are known to inhibit prolactin but there are no reports of decreased lactation with CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP). Ergotamine is excreted in breast milk and may cause symptoms of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, weak pulse and unstable blood pressure in nursing infants. Because of the potential for serious adverse reactions in nursing infants from CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-14"></a><p></p>
<h1>Pediatric Use:</h1>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-15"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Cardiovascular:</span> Vasoconstrictive complications of a serious nature may occur at times. These include <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, absence of pulse, <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold extremities</span>, <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>, precordial distress and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, EKG changes and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span>. Although these effects occur most commonly with long-term therapy at relatively high doses, they have also been reported with short-term or normal doses. Other cardiovascular adverse effects include transient <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Bold">Neurological:</span>  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold">Allergic:</span> <span class="product-label-link" type="condition" conceptid="4026047" conceptname="Sacral edema">Localized edema</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</p>
<p><span class="Bold">Fibrotic Complications:</span> (see <span class="Bold">WARNINGS</span>).</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-16"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">There have been reports of drug abuse and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in patients on CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) therapy. Due to the chronicity of <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headaches</span>, it is imperative that patients be advised not to exceed recommended dosages with long-term use to avoid <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span>.  (<span class="Italics">See </span><span class="Bold">PRECAUTIONS</span>)</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-17"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The toxic effects of an acute overdosage of CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) are due primarily to the ergotamine component. The amount of caffeine is such that its toxic effects will be overshadowed by those of ergotamine. Symptoms include <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> of the extremities associated with diminished or absent peripheral pulses; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. A case has been reported of reversible bilateral <span class="product-label-link" type="condition" conceptid="435269" conceptname="Optic papillitis">papillitis</span> with ring scotomata in a patient who received five times the recommended daily adult dose over a period of 14 days.</p>
<p>Treatment consists of removal of the offending drug by induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, gastric lavage, and catharsis. Maintenance of adequate pulmonary ventilation, correction of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and blood pressure are important considerations. Treatment of peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> should consist of warmth, but not heat, and protection of the ischemic limbs. Vasodilators may be beneficial but caution must be exercised to avoid aggravating an already existent <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-18"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Procedure:  For the best results, dosage should start at the first sign of an attack.  Adults:  Take 2 tablets at the start of attack; 1 additional tablet every ½ hour, if needed for full relief (maximum 6 tablets per attack, 10 per week).</p>
<p><span class="Bold">Maximum Adult Dosage:</span>  Total dose for any one attack should not exceed 6 tablets.  Total weekly dosage should not exceed 10 tablets.  Ergotamine tartrate and caffeine tablets should not be used for chronic daily administration.  In carefully selected patients, with due consideration of maximum dosage recommendations, administration of the drug at bedtime may be an appropriate short-term preventive measure.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-19"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) for oral administration are available as:</p>
<p><span class="Bold">1 mg/100 mg: </span> round tablets, film coated beige, debossed SZ 183 on one side and plain on the reverse side and supplied as:</p>
<p>Box of 30 Unit-Dose Tablets                      NDC 0179-0089-70</p>
<p>Store at 20°-25°C (68°-77°F) (see USP controlled room temperature).</p>
<p>Dispense in a tight, light-resistant container. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-20"></a><p></p>
<p class="First">Manufactured by:<br>SANDOZ INC.<br>Princeton, NJ  08540</p>
<p>Repackaged by:<br>KAISER FOUNDATION HOSPITALS<br>Livermore, CA 94551</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1>CAFERGOT<span class="Sup">®</span>(ergotamine tartrate and caffeine tablets, USP) Package Label</h1>
<p class="First"><img alt="CAFERGOT (ergotamine tartrate and caffeine tablets, USP) Package Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1c066197-dea6-4705-9b4a-8703dd564a2a&amp;name=Cafergot-03.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAFERGOT 		
					</strong><br><span class="contentTableReg">ergotamine tartrate and caffeine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0179-0089(NDC:0781-5405)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERGOTAMINE TARTRATE</strong> (ERGOTAMINE) </td>
<td class="formItem">ERGOTAMINE TARTRATE</td>
<td class="formItem">1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CAFFEINE</strong> (CAFFEINE) </td>
<td class="formItem">CAFFEINE</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO
</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (Beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SZ;183</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0179-0089-70</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA084294</td>
<td class="formItem">04/21/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>KAISER FOUNDATION HOSPITALS
							(053052619)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">KAISER FOUNDATION HOSPITALS</td>
<td class="formItem"></td>
<td class="formItem">053052619</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>eb4f1418-2342-4174-a448-1335dea53deb</div>
<div>Set id: 1c066197-dea6-4705-9b4a-8703dd564a2a</div>
<div>Version: 1</div>
<div>Effective Time: 20110425</div>
</div>
</div> <div class="DistributorName">KAISER FOUNDATION HOSPITALS</div></p>
</body></html>
